Vaccines Articles
A new tobacco-based seasonal influenza vaccine being developed by Mitsubishi Tanabe Pharma and currently in Phase III studies could potentially rival traditional chicken egg-based vaccines.
Findings from a first in-human study for a new malaria vaccine candidate have shown a robust immune response while significantly delaying parasitemia.
Preliminary overall 2015-16 influenza vaccine effectiveness was 59 percent, according to the Centers for Disease Control and Prevention.
A new form of hybridized sound waves developed by Australian researchers may allow drugs and vaccines to be delivered to the body through a nebulizer in a fine mist inhaled into the lungs.
Two studies presented at the International Conference on Emerging Infectious Diseases show that the influenza vaccine can protect for six months, last throughout the flu season and reduce hospitalization in children.
